CSPCY (CSPC Pharmaceutical Group) Total Assets: $6,630 Mil (As of Dec. 2025)


CSPCY CSPC Pharmaceutical Group Ltd CSPCY
79 GF Score
Price $3.55
GF Value $3.31
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is CSPC Pharmaceutical Group Total Assets?

CSPC Pharmaceutical Group CSPCY +1.18% 79 Total Assets is $6,630 Mil as of Dec. 2025. GuruFocus rates CSPCY with a GF Score™ of 79/100 and a GF Value™ of $3.31 (Fairly Valued). The stock has 4 warning signs investors should review.

CSPC Pharmaceutical Group's Total Assets for the quarter that ended in Dec. 2025 was $6,630 Mil.

During the past 12 months, CSPC Pharmaceutical Group's average Total Assets Growth Rate was 8.30% per year. During the past 3 years, the average Total Assets Growth Rate was 10.30% per year. During the past 5 years, the average Total Assets Growth Rate was 10.50% per year. During the past 10 years, the average Total Assets Growth Rate was 14.90% per year.

During the past 13 years, CSPC Pharmaceutical Group's highest 3-Year average Total Assets Growth Rate was 91.40%. The lowest was -36.00%. And the median was 11.85%.

Total Assets is connected with ROA %. CSPC Pharmaceutical Group's annualized ROA % for the quarter that ended in Dec. 2025 was 3.18%. Total Assets is also linked to Revenue through Asset Turnover. CSPC Pharmaceutical Group's Asset Turnover for the quarter that ended in Dec. 2025 was 0.13.

CSPC Pharmaceutical Group  (OTCPK:CSPCY) Total Assets Explanation

Total Assets is connected with ROA %.

CSPC Pharmaceutical Group's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=210.54/( (0+6630.213)/ 1 )
=210.54/6630.213
=3.18 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

CSPC Pharmaceutical Group's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=868.2/( (0+6630.213)/ 1 )
=868.2/6630.213
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

CSPC Pharmaceutical Group Total Assets Related Terms

CSPC Pharmaceutical Group Total Assets Historical Data

* Premium members only.

The historical data trend for CSPC Pharmaceutical Group's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group Total Assets Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,454.54 5,991.33 6,481.92 6,096.80 6,630.21

CSPC Pharmaceutical Group Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 6,406.66 0.00 6,630.21 0.00
CSPCY
79GF Score
CSPC Pharmaceutical Group Ltd CSPCY
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSPC Pharmaceutical Group Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

CSPC Pharmaceutical Group's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=4905.457+1724.755
=6,630

CSPC Pharmaceutical Group's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=4905.457+1724.755
=6,630

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $6,630 Mil mean?
CSPC Pharmaceutical Group (CSPCY) has a Total Assets of $6,630 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on CSPC Pharmaceutical Group and its competitors.
Is CSPC Pharmaceutical Group's Total Assets too high?
CSPC Pharmaceutical Group's current Total Assets is $6,630 Mil. Overall, CSPC Pharmaceutical Group has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's Total Assets compare to LLY and JNJ?
CSPC Pharmaceutical Group's Total Assets of $6,630 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on CSPC Pharmaceutical Group and its competitors. CSPC Pharmaceutical Group's current Total Assets is $6,630 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Fairly Valued. The stock's GF Value™ is $3.31, compared to a current price of $3.55 — trading 7.3% above its estimated fair value. The current Total Assets is $6,630 Mil. CSPC Pharmaceutical Group's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current Total Assets is $6,630 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued. The current stock price of $3.55 is trading 7.3% above its estimated GF Value™ of $3.31. GuruFocus considers CSPC Pharmaceutical Group to be Fairly Valued.

Key valuation signals for CSPCY:

  • Total Assets: $6,630 Mil
  • GF Value™: $3.31 vs. price of $3.55 (7.3% above fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSPC Pharmaceutical Group Business Description

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
79GF Score

Get the complete analysis for CSPCY

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price
$3.31
GF Value